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objective of this research is to estimate current and future burden
of this condition using the UK as an example. METHODS: Age
and sex related prevalence rates have been applied to current and
forecast population data to estimate future prevalence. A pub-
lished assessment of patient costs is used to derive an estimate
of economic burden. RESULTS: Our analysis indicates that 4.7
million people are estimated to have OAB in the UK. Although
few males are treated for this disease, male prevalence is esti-
mated to account for up to 45% of the total (treated and
untreated) OAB population. UK government population fore-
casts for 2020 imply a 27% growth in OAB prevalence with male
prevalence increasing faster than that of females. Using published
data for average annual patient costs for OAB patients, the
current cost burden of OAB in the UK is estimated to exceed
£800m per annum. CONCLUSIONS: OAB is a highly prevalent
condition imposing a substantial economic burden, which will
increase with demographic shifts towards an aging population.
If the prevalence of OAB risk factors including diabetes,
smoking, and UTIs increases over time, then it is reasonable to
expect that age related OAB prevalence will increase with time.
Our forecast prevalence may therefore under-estimate future
burden because our analysis assumes that age related prevalence
is constant over time. Assuming constant costs per patient, the
economic burden will increase in line with our prevalence fore-
casts. Given that many sufferers, especially males, do not cur-
rently seek treatment, the future cost burden may also have been
underestimated.
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OBJECTIVES: In Australia, sirolimus is indicated where with-
drawal of cyclosporin (CsA) is appropriate and intended within
four months of renal transplantation. In one clinical trial,
patients randomized three months after transplantation experi-
enced signiﬁcantly lower nephrotoxicity and serum creatinine
(SC) with sirolimus and CsA withdrawal compared to a com-
bined low-dose sirolimus and CsA regimen. The long-term cost-
effectiveness of sirolimus was estimated in a cost-utility analysis
based on this trial. METHODS: A Markov model was used to
estimate sirolimus’ impact on health outcomes and direct costs
to the Australian health system for a patient’s lifetime. Graft sur-
vival rates were derived from the clinical trial data (years 1–3),
extrapolated from 6-month SC using Australia and New Zealand
Dialysis and Transplant Registry (ANZDATA) estimates (years
4–6) and assumed an exponential decay function (years 7+).
Probabilities of regraft, acute rejection and death were derived
from the clinical trial and ANZDATA data. Quality-adjusted life
years (QALYs) were the product of years with a functioning or
failed graft and time trade-off derived utilities for those health
states. Resource consequences included immunosuppressants
and inpatient and outpatient services, and were veriﬁed by a
panel of clinical experts. Estimated costs were mean national
costs to the Australian health system. RESULTS: With CsA with-
drawal, the estimated lifetime cost of immunosuppressants is
$61,804 greater, the cost of events $35,333 lower, and 0.447
additional QALYs are accrued (per-patient means). The base case
cost per additional QALY gained over combination therapy is
$59,259 and most sensitive to the cost and disutility associated
with dialysis. CONCLUSIONS: Sirolimus is associated with
greater SC reduction than CsA and is thereby expected to lead
to higher rates of graft and patient survival. It is estimated that
with CsA withdrawal, sirolimus will reduce lifetime health care
costs, increase quality-adjusted survival, and is potentially cost-
effective for recently transplanted patients.
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OBJECTIVES: Previous analyses have shown that the cost of
managing chronic kidney disease (CKD) increases with worsen-
ing disease. In this study, we were interested in the relationship
between cost of care, CKD and comorbidities (proteinuria, 
coronary artery disease, congestive heart failure (CHF), dia-
betes mellitus, hypertension, anemia, and hyperlipidemia).
METHODS: Cases were >17 years of age, and had a GFR (esti-
mated by MDRD) greater than 15ml/min/1.73m2 and less than
90ml/min/1.73m2 (the index GFR), followed by a second GFR
below 90ml/min/1.73m2 at the ﬁrst creatinine measurement that
occurred at least 90 days later; controls were matched on age
and gender. Four disease categories were established: Controls;
60–89 (GFR 2); 30–59 (GFR 3); and 15–29 (GFR 4). Subjects
were followed for 1 year and costs were annualized and weighted
by months of observation. Linear regression was used to predict
costs as a function of disease category, controlling for comor-
bidities. RESULTS: We found that patients with early and mild
chronic kidney disease (GFR 30–89) consume approximately
$2000 more per year in medical care than their age- and sex-
matched control patients without recognized kidney disease after
adjusting for comorbid conditions, while those with severe
disease (GFR 15–29) consume more than twice that amount. Of
the comorbid conditions that we evaluated, anemia, congestive
heart failure, and proteinuria were among the strongest inde-
pendent predictors of total medical costs. These conditions also
modiﬁed the total cost for each stage of chronic kidney disease.
CONCLUSION: Patients with CKD have a greater total cost of
care than age and gender matched controls, even after control-
ling for CKD-related comorbidities. Combined with increasing
incidence of kidney disease, these data strongly argue the need
for better understanding of cost-effective treatment programs in
CKD.
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OBJECTIVE: The best therapeutic approach to treating lupus
nephritis (LN) remains contentious; therefore different thera-
peutic approaches have been embraced over the years. The
purpose of this pharmacoeconomic decision analysis is to
compare the use of intermittent intravenous cyclophosphamide
plus prednisone versus oral azathioprine plus prednisone for the
treatment of LN and to determine which regimen is more bene-
ﬁcial in terms of cost. METHODS: The third party payer per-
spective was used to estimate the costs of treating LN, after
deciding to prescribe either regimen. Costs were obtained from
various sources including primary literature and clinical trials.
Analyses were based on actual costs for treatment of LN and
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include drug costs, drug administration costs, physician charges
for monitoring, and cost for dialysis or kidney transplants for
those progressing to ESRD. Costs were modiﬁed to 2003 US$
using the medical care component of the Consumer Price Index
adjustment for inﬂation ratio, and discounted at 3%. Cost were
calculated on a per patient basis and then annualized. Statistical
comparisons of costs were done using a nonparametric Mann-
Whitney U test. Sensitivity analyses were also performed.
RESULTS: Lupus nephritis patients receiving azathioprine plus
prednisone had signiﬁcantly lower overall treatment costs,
demonstrating a $14,580 cost savings per patient over the 10-
year evaluation period. The Mann-Whitney U test indicated that
the azathioprine and cyclophosphamide arm costs $101,003.25
and $115,583.54, correspondingly were signiﬁcantly different 
(P = 0.0091, 95% CI: $482, $2484). The mean difference
between the treatment arms was $1453. Sensitivity analyses con-
ducted on the drug costs, and the probability of discontinuation
of cyclophosphamide did not change the results of the model.
CONCLUSIONS: The results indicate that azathioprine signiﬁ-
cantly reduced the total long-term costs to the third party 
payer. The decision analysis supports the use of azathioprine 
plus prednisone as induction therapy in the treatment of lupus
nephritis.
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OBJECTIVE: Uncomplicated urinary tract infections are a
highly prevalent condition among college-age women. In addi-
tion, resistance to commonly used treatments is increasing. This
study compares antibiotic cost-effectiveness at a college health
clinic. METHODS: Treatment encounters at the clinic were
reviewed for prescribing and effectiveness data. Cost estimates
include provider visit, laboratory costs, and the cost of pre-
scribed medication. Two decision-analysis models were con-
structed, one including all relevant costs and the other including
only the portion of the cost absorbed by the health clinic.
RESULTS: There were 436 cases of urinary tract infection at the
health clinic in 2001–2002. Cases were included if they were
uncomplicated and there was no prior antibiotic allergy, resis-
tance, or risk factors for resistance. Of the 91 included cases, 51
were treated with sulfamethoxazole/trimethoprim (SMX/TMP),
33 were treated with nitrofurantoin and 7 were treated with
ciproﬂoxacin. Cost-effectiveness results were based on evalua-
tion of drug cost, potential for allergy, and clinical cure rates.
Despite 23% laboratory resistance and 9% allergy, 79% of
patients treated with SMX/TMP were successfully cured. Nitro-
furantoin was effective in 97% of patients and ciproﬂoxacin was
effective in 100% of patients with few cases of allergy. Treat-
ment cost per patient was $144 for SMX/TMP, $169 for nitro-
furantion and $173 for ciproﬂoxacin. The cost per patient
absorbed by the health clinic was $55 for SMX/TMP and $65
and $58 for nitrofurantoin and ciproﬂoxacin respectively. CON-
CLUSIONS: Most of the patients treated with SMX/TMP were
successfully cured, despite increasing laboratory resistance rates.
We found SMX/TMP to be the most cost-effective treatment for
uncomplicated urinary tract infections. It is important to remem-
ber the importance of clinical success and laboratory resistance
when constructing such models, and the results are likely to vary
widely.
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OBJECTIVES: To study the impact of EPO therapy on direct
medical cost by comparing anemic NDCKD patients treated with
EPO to those not treated. METHODS: Anonymous medical and
pharmacy claims data in January 1998–June 2001 from seven
large companies were used. After excluding patients receiving
blood transfusions, 66 NDCKD patients with at least two
anemia claims were identiﬁed as anemic. Of them, 30 patients
treated with EPO prior to dialysis were classiﬁed as the EPO
group, while the remaining 36 were the control group. Descrip-
tive statistics were generated to compare the direct medical cost
of the EPO and control groups prior to dialysis and in the ﬁrst
six months after dialysis initiation. RESULTS: Baseline age,
gender, and comorbidities did not signiﬁcantly differ between 
the two groups. The average monthly total medical cost for 
the control group was higher than that for the EPO group in
both the pre- and post-dialysis phases ($2916.5 vs. $2177.9,
$11,245.7 vs. $10,143.8, respectively), albeit not reaching a 5%
signiﬁcance level. Before dialysis, the monthly inpatient and out-
patient costs were higher in the control than EPO group
($1541.8 vs. $795.2 inpatient, p > 0.05; $1247.3 vs. $918.8 out-
patient, p < 0.05). In contrast, average monthly drug cost was
higher for the EPO group ($463.9 vs. $127.4, p < 0.05). Similar
patterns were observed in the dialysis phase. CONCLUSIONS:
An overall trend in the reduction of medical cost was seen for
EPO-treated anemic NDCKD patients compared to those not
treated. The cost savings for the EPO group for inpatient and
outpatient services outweigh the higher drug cost. Although the
differences in total medical cost are not statistically different
between EPO and control groups, this may be due to the small
sample size. Further research with larger samples are warranted.
URINARY/KIDNEY DISEASES/DISORDERS
URINARY/KIDNEY DISEASES/DISORDERS—Quality of
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OBJECTIVES: Prevalence rates of 16% have been reported for
overactive bladder (OAB). Despite the high prevalence of OAB,
it is both an under-diagnosed and underreported condition. Once
symptoms develop, many individuals construct their preferences
for treatment after considering the quality of life (QOL) effects
of OAB and whether they possess prescription drug insurance.
The purpose of this study was to examine the relative impor-
tance patients place on QOL domains and prescription drug 
coverage in their decision to pharmacologically manage OAB
symptoms. METHODS: A questionnaire consisting of nine
hypothetical proﬁles was used to elicit preferences. The sample
taken from a large clinic consisted of 134 patients having symp-
toms of OAB. To be included, participants were either male or
female and were not taking medications to treat their symptoms.
